Literature DB >> 10414496

High prevalence of a 30-base pair deletion in the Epstein-Barr virus (EBV) latent membrane protein 1 gene and of strain type B EBV in Mexican classical Hodgkin's disease and reactive lymphoid tissue.

S Dirnhofer1, A Angeles-Angeles, C Ortiz-Hidalgo, E Reyes, E Gredler, J Krugmann, F Fend, L Quintanilla-Martinez.   

Abstract

Depending on geographic location and patient age Hodgkin's disease (HD) is associated with Epstein-Barr virus (EBV), mostly type A EBV, in 20% to 100%. The highest prevalence occurs in children of developing countries. Molecular analysis of the oncogene coding for the latent membrane protein 1 (LMP-1) revealed a 30-base pair (bp) deletion in up to 46% of EBV-positive HD. We investigated the presence of EBV in a series of Mexican classical HD (n = 57) and reactive lymphoid tissues (n = 20) from a private and a public hospital with special emphasis on the prevalence of the 30-bp deletion and the type of EBV. EBV infection was analyzed at the cellular level by Epstein-Barr encoded early RNA transcripts (EBER) in situ hybridization (ISH) and by LMP-1 protein immunohistochemistry (IHC). Molecular analysis of the LMP-1 gene configuration was performed by polymerase chain reaction (PCR) with primers spanning the site of the deletion and subsequent Southern and/or dot blot hybridization using wild-type and deletion-specific probes. The prevalence of type A and type B EBV was investigated by PCR-analysis for divergence in the coding region of Epstein-Barr nuclear antigen (EBNA)-2. EBV was detected in Hodgkin- and Reed-Sternberg cells (H-RS) by LMP-1 IHC and/or EBER ISH in 35/57 (61%) Mexican HD including 18/32 (56%) with nodular sclerosis, 15/20 (75%) with mixed cellularity and 2/4 (50%) with lymphocyte depletion. In addition, LMP-1 gene sequences were detected by PCR in 9 cases of HD without LMP/EBER expression by H-RS cells and in 17/20 (85%) reactive lymph nodes, supposedly originating from rare latently infected B cells. Surprisingly, the 30-bp LMP-1 deletion was found in 28/35 (80%) EBV-positive HD. This deletion, however, was also found in all 9 (100%) HD with H-RS cells negative for EBV and in 10/17 (59%) reactive lymph nodes. Thus, the overall LMP-1 del prevalence in reactive tissue is 73% (19/26). Typing of EBV was successful in 26 cases of EBV-positive HD, 10 of these were infected by type B EBV (38%). Of the reactive lymphoid tissue, 9 (47%) were infected by type A, and 10 (53%) by type B; All 20 cases (100%) associated with type B, whether neoplastic or reactive, displayed the LMP-1 del variant compared with 18/25 (72%) infected by type A EBV. To our knowledge, this is the highest incidence for both the LMP-1 deletion variant and the infection by type B EBV in HD reported so far worldwide. Our data suggest that EBV infection contributes to the pathogenesis of the majority of Hodgkin's disease cases in Mexico. The specific tumorigenic role of the LMP-1 deletion variant, however, is doubtful with regard to its high frequency in nonneoplastic lesions. Moreover, type B infection frequently occurs in Mexican HD and reactive lymphoid tissue and is consistently associated with the deletion variant pointing to a pathogenetic role of this combined genotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10414496     DOI: 10.1016/s0046-8177(99)90138-7

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Distinctive Epstein-Barr virus variants associated with benign and malignant pediatric pathologies: LMP1 sequence characterization and linkage with other viral gene polymorphisms.

Authors:  Mario Alejandro Lorenzetti; Magdalena Gantuz; Jaime Altcheh; Elena De Matteo; Paola Andrea Chabay; María Victoria Preciado
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

2.  Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America.

Authors:  Ivonne A Montes-Mojarro; Bo-Jung Chen; Ana F Ramirez-Ibarguen; Carmen M Quezada-Fiallos; Wendy B Pérez-Báez; Daniela Dueñas; Sandro Casavilca-Zambrano; Marcela Ortiz-Mayor; Erica Rojas-Bilbao; Hernan García-Rivello; Maria F Metrebian; Marina Narbaitz; Carlos Barrionuevo; Carmen Lome-Maldonado; Irina Bonzheim; Falko Fend; Julia Steinhilber; Leticia Quintanilla-Martinez
Journal:  Mod Pathol       Date:  2019-12-10       Impact factor: 7.842

3.  The Epstein-Barr virus latent membrane protein-1 (LMP1) 30-bp deletion and XhoI-polymorphism in nasopharyngeal carcinoma: a meta-analysis of observational studies.

Authors:  Vivaldo G da Costa; Ariany C Marques-Silva; Marcos L Moreli
Journal:  Syst Rev       Date:  2015-04-13

Review 4.  EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts.

Authors:  Stefan D Dojcinov; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Pathogens       Date:  2018-03-07

5.  Comparison between presence of epstein barr virus in nodal and extra nodal diffuse large B cell lymphoma of head and neck, an Iranian experience.

Authors:  Mohammad Javad Ashraf; Alireza Makarempour; Ahmad Monabati; Negar Azarpira; Bijan Khademi; Afsoon Hakimzadeh; Elham Abedi; Bita Valibeigi
Journal:  Iran Red Crescent Med J       Date:  2012-12-06       Impact factor: 0.611

6.  Hodgkin lymphoma incidence in California Hispanics: influence of nativity and tumor Epstein-Barr virus.

Authors:  S L Glaser; C A Clarke; E T Chang; J Yang; S L Gomez; T H Keegan
Journal:  Cancer Causes Control       Date:  2014-04-11       Impact factor: 2.532

Review 7.  EBV and the Pathogenesis of NK/T Cell Lymphoma.

Authors:  Ivonne A Montes-Mojarro; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Cancers (Basel)       Date:  2021-03-19       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.